Prognostic factors and outcome in women with uterine sarcoma

European Journal of Surgical Oncology

Volumn 33, Issue 1, 2007, Pages 91-95

  Denschlag, D ^a   Masoud, I ^a   Stanimir, G ^a   Gilbert, L ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Adjuvant treatment; ESS; LMS; MMT; Outcome; Prognostic factors; Uterine sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MEGESTROL ACETATE;

ABDOMINAL HYSTERECTOMY; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENDOMETRIUM SARCOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MIXED MULLERIAN TUMOR; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TREATMENT OUTCOME; UTERUS SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LEIOMYOSARCOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SARCOMA, ENDOMETRIAL STROMAL; SURVIVAL RATE;

EID: 33846534068     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.11.012     Document Type: Article

References (21)

1. Platz C.E., and Benda J.A. Female genital tract cancer. Cancer 75 (1995) 270
2. Major F.J., Blessing J.A., Silverberg S.G., et al. Prognostic factors in early-stage uterine sarcoma. Gynecol Oncol Group Study Cancer 71 (1993) 1702
3. Marchese M.J., Liskow A.S., Crum C.P., McCaffrey R.M., and Frick II H.C. Uterine sarcomas: a clinicopathologic study, 1965-1981. Gynecol Oncol 18 (1984) 299
4. Gadducci A., Sartori E., Landoni F., et al. The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases. Eur J Gynaecol Oncol 23 (2002) 295
5. Livi L., Andreopoulou E., Shah N., et al. Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998. Clin Oncol (R Coll Radiol) 16 (2004) 261
6. Olah K.S., Dunn J.A., and Gee H. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. Br J Obstet Gynaecol 99 (1992) 590
7. Kelly K.L., and Craighead P.S. Characteristics and management of uterine sarcoma patients treated at the Tom Baker Cancer Centre. Int J Gynecol Cancer 15 (2005) 132
8. Nordal R.R., Kristensen G.B., Stenwig A.E., Nesland J.M., Pettersen E.O., and Trope C.G. An evaluation of prognostic factors in uterine carcinosarcoma. Gynecol Oncol 67 (1997) 316
9. Sagae S., Yamashita K., Ishioka S., et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology 67 (2004) 33
10. Reed N.S., Mangioni C., Malmstrom H., et al. First results of a randomized trial comparing radiotherapy versus observation postoperatively in patients with uterine sarcomas. An EORTC-GCG Study (abstract). Int J Gynecol Cancer 13 suppl 1 (2003) 4
11. Ferrer F., Sabater S., Farrus B., et al. Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Group Oncologic Catala-Occita. Int J Radiat Oncol Biol Phys 44 (1999) 47-52
12. Olah KS, Gee H, Blunt S, Dunn JA, Kelly K, Chan KK. Retrospective analysis of 318 cases of uterine sarcoma. Eur J Cancer1991; 27:1095-9.
13. Omura G.A., Blessing J.A., Major F., et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol 3 (1985) 1240-1245
14. Piver M.S., Lele S.B., Marchetti D.L., and Emrich L.J. Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas. J Surg Oncol 38 (1988) 233
15. Sutton G.P., Blessing J.A., Rosenshein N., Photopulos G., and Disaia P.J. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol 161 (1989) 309-312
16. Sutton G.P., Blessing J.A., Barrett R.J., and McGehee R. Phase II trial of ifosfamide and mesna in leimyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 166 (1992) 556-559
17. Chu M.C., Mor G., Lim C., Zheng W., Parkash V., and Schwartz P.E. Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol 90 (2003) 170-176
18. Kelley T.W., Borden E.C., and Goldblum J.R. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study. Appl Immunohistochem Mol Morphol 12 (2004) 338-341
19. Wade K., Quinn M.A., Hammond I., Williams K., and Cauchi M. Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol Oncol 39 (1990) 364-367
20. Burke C., and Hickey K. Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue. Obstet Gynecol 104 (2004) 1182-1184
21. Leunen M., Breugelmans M., De Sutter P., Bourgain C., and Amy J.J. Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol Oncol 95 (2004) 769-771